Relationship between alirocumab, PCSK9 and LDL-C levels: results from the odyssey mono phase 3 trial of alirocumab 75 mg every 2 weeks

Abstract

Peer reviewed

M. Farnier, J.J.P. Kastelein, E. Roth, M.R. Taskinen, H.N. Ginsberg, H.M. Colhoun, J.G. Robinson, L. Merlet, A. Brunet, R. Pordy, …

Atherosclerosis, Vol.235(2), pp.e34-e35

08/2014

DOI: 10.1016/j.atherosclerosis.2014.05.070

View Online

Title: Subtitle: Relationship between alirocumab, PCSK9 and LDL-C levels: results from the odyssey mono phase 3 trial of alirocumab 75 mg every 2 weeks
Creators: M. Farnier - Département d'Endocrinologie et de Lipidologie, Point Medical, Dijon, France
J.J.P. Kastelein - Academic Medical Center
E. Roth - Sterling Research Group
M.R. Taskinen - University of Helsinki
H.N. Ginsberg - Columbia University
H.M. Colhoun - University of Iowa
J.G. Robinson - University of Iowa
L. Merlet - Sanofi
A. Brunet - Sanofi
R. Pordy - Regeneron
M.T. Baccara-Dinet - Sanofi
Resource Type: Abstract
Publication Details: Atherosclerosis, Vol.235(2), pp.e34-e35
Publisher: Elsevier Ireland Ltd
DOI: 10.1016/j.atherosclerosis.2014.05.070
ISSN: 0021-9150
eISSN: 1879-1484
Language: English
Date published: 08/2014
Academic Unit: Epidemiology; Fraternal Order of Eagles Diabetes Research Center
Record Identifier: 9984364654502771

10 Record Views